prikaz prve stranice dokumenta Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
  Download
PDF 397.4 KB
Scientific paper - Review paper
Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
Diabetology, 5 (2024), 4; 406-429. https://doi.org/10.3390/diabetology5040031
Knežević, Sandra; Filippi-Arriaga, Francesca; Belančić, Andrej; Božina, Tamara; Mršić-Pelčić, Jasenka; Vitezić, Dinko

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Knežević, S., Filippi Arriaga, F., Belančić, A., Božina, T., Mršić Pelčić, J. & Vitezić, D. (2024). Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review. Diabetology, 5. (4), 406-429. doi: 10.3390/diabetology5040031

Knežević, Sandra, et al. "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review." Diabetology, vol. 5, no. 4, 2024, pp. 406-429. https://doi.org/10.3390/diabetology5040031

Knežević, Sandra, Francesca Filippi Arriaga, Andrej Belančić, Tamara Božina, Jasenka Mršić Pelčić and Dinko Vitezić. "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review." Diabetology 5, no. 4 (2024): 406-429. https://doi.org/10.3390/diabetology5040031

Knežević, S., et al. (2024) 'Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review', Diabetology, 5(4), pp. 406-429. doi: 10.3390/diabetology5040031

Knežević S, Filippi Arriaga F, Belančić A, Božina T, Mršić Pelčić J, Vitezić D. Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review. Diabetology [Internet]. 2024 September 03 [cited 2024 December 28];5(4):406-429. doi: 10.3390/diabetology5040031

S. Knežević, F. Filippi Arriaga, A. Belančić, T. Božina, J. Mršić Pelčić and D. Vitezić, "Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review", Diabetology, vol. 5, no. 4, pp. 406-429, September 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:491768. [Accessed: 28 December 2024]

Metadata
Title (english)Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review
AuthorSandra Knežević
AuthorFrancesca Filippi-Arriaga
AuthorAndrej Belančić
AuthorTamara Božina
AuthorJasenka Mršić-Pelčić
AuthorDinko Vitezić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Pharmacology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Clinical Pharmacology and Toxicology
Abstract (english)
Metabolic syndrome (MetS) presents a significant global health challenge, characterized by a cluster of metabolic alterations including obesity, hypertension, insulin resistance/dysglycemia, and atherogenic dyslipidemia. Advances in understanding and pharmacotherapy have added complexity to MetS management, particularly concerning drug interactions and pharmacogenetic variations. Limited literature exists on drug–drug–gene interactions (DDGIs) and drug–drug–transporter gene interactions (DDTGIs), which can significantly impact pharmacokinetics and pharmacodynamics, affecting treatment outcomes. This narrative review aims to address the following three key objectives: firstly, shedding a light on the PK metabolism, transport, and the pharmacogenetics (PGx) of medicines most commonly used in the MetS setting (relevant lipid-lowering drugs, antihypertensives and antihyperglycemics agents); secondly, exemplifying potential clinically relevant pharmacokinetic drug interactions, including drug–drug interactions, DDGIs, and DDTGIs; and, thirdly, describing and discussing their potential roles in clinical practice. This narrative review includes relevant information found with the use of interaction checkers, pharmacogenetic databases, clinical pharmacogenetic practice guidelines, and literature sources, guided by evidence-based medicine principles.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDiabetology
Numberingvol. 5, no. 4, pp. 406-429
e-ISSN2673-4540
DOIhttps://doi.org/10.3390/diabetology5040031
URN:NBNurn:nbn:hr:184:491768
Publication2024-09-03
Document URLhttps://www.mdpi.com/2673-4540/5/4/31
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-09-13 11:02:35